International Classification of Diseases (ICD)-11

In 2008 the ILDS was invited to be the Dermatology Topic Advisory Group (TAG) leader for the ICD-11. Over the last decade we have co-ordinated the TAG with the hard work of the dedicated Dr Robert Chalmers.

ICD-11 is fundamentally different from its predecessors. It comprises of two elements: the ICD-11 Foundation, and ICD-11 for Mortality and Morbidity Statistics (MMS).

The ICD-11 Foundation is a family of classifications which are polyhierarchical; any one disease concept (entity) has a single Unique Identifier (URI) but may have multiple hierarchical parents, so that it can be represented in and retrieved from more than one location.

ICD-11 MMS is the direct replacement for ICD-10 as the international statistical reference and provides a concise “tabular” list of entities extracted from the ICD-11 Foundation, where any one concept can be placed in only one location with a single hierarchical parent.

In early 2017 the ILDS invited Members to participate in field-testing ICD-11. Over 80 dermatologists from around the world responded. They were asked to judge whether the diagnoses of 50 unselected patients they had recently seen could be adequately coded using ICD‑11. Suitable diagnostic terms could be found for 98% of nearly 4,000 patient records reviewed. Some 25 additional synonyms and 11 missing concepts were identified for addition to ICD-11. This was a welcome endorsement of the work that has gone into this project, to which so many people have contributed.

On 25 May 2019, the World Health Assembly[1] officially adopted the eleventh revision of the International Classification of Diseases (ICD-11). The ICD-11 will come into effect on 1 January 2022.

[1] The decision-making body of the World Health Organization